Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) has issued an announcement.
Oxford Biomedica has confirmed that preliminary talks are continuing with EQT over a possible all-cash takeover, after the private equity firm’s unsolicited approach for the entire issued and to-be-issued share capital last month. The U.K. Takeover Panel has granted an extension of the “put up or shut up” deadline to 5 p.m. on 25 February 2026, giving EQT more time to decide whether to make a firm offer or walk away.
The company cautioned that there is no certainty an offer will be made or on what terms, and urged shareholders to take no action until further notice. The extension underscores ongoing strategic interest in specialist cell and gene therapy CDMOs and could influence Oxford Biomedica’s valuation and bargaining position as it weighs its options with the support of advisers Evercore and Jefferies.
The most recent analyst rating on (GB:OXB) stock is a Hold with a £904.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on GB:OXB Stock
According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.
The score is primarily held back by weak financial performance—ongoing losses, negative cash flows, and high leverage—despite strong recent revenue growth. Technicals are supportive due to a strong uptrend and positive MACD, but very overbought RSI/Stoch readings add near-term downside risk. Valuation is constrained by negative earnings and the absence of a dividend yield.
To see Spark’s full report on GB:OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica is a global, quality-focused contract development and manufacturing organisation specialising in cell and gene therapy viral vectors. With 30 years of experience and proprietary technologies such as its TetraVecta lentiviral system, the FTSE4Good-listed group serves leading pharma and biotech clients from facilities in the U.K., France and the U.S. across development to commercial manufacturing.
Average Trading Volume: 330,141
Technical Sentiment Signal: Buy
Current Market Cap: £977.5M
See more insights into OXB stock on TipRanks’ Stock Analysis page.